Qsemble Capital Management LP Sells 1,154 Shares of Masimo Co. (NASDAQ:MASI)

Qsemble Capital Management LP lessened its position in Masimo Co. (NASDAQ:MASI) by 41.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,617 shares of the medical equipment provider’s stock after selling 1,154 shares during the quarter. Qsemble Capital Management LP’s holdings in Masimo were worth $216,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of MASI. Lazard Asset Management LLC raised its holdings in Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 573 shares during the period. Tidal Investments LLC raised its holdings in Masimo by 14.1% in the 1st quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider’s stock worth $320,000 after acquiring an additional 269 shares during the period. Farallon Capital Management LLC raised its holdings in Masimo by 13.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares during the period. GAMMA Investing LLC raised its holdings in Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares during the period. Finally, Juncture Wealth Strategies LLC increased its holdings in shares of Masimo by 294.3% during the 2nd quarter. Juncture Wealth Strategies LLC now owns 7,992 shares of the medical equipment provider’s stock worth $1,007,000 after purchasing an additional 5,965 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Price Performance

Shares of Masimo stock opened at $170.89 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm’s 50-day simple moving average is $147.03 and its 200-day simple moving average is $129.03. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27. The firm has a market cap of $9.15 billion, a P/E ratio of 117.86 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, research analysts expect that Masimo Co. will post 4.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on MASI shares. BTIG Research boosted their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their price objective on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Finally, Wells Fargo & Company boosted their price objective on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $167.00.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.